CLINICAL TRIALS PROFILE FOR VIRAMUNE

All Clinical Trials for VIRAMUNE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002166 ↗	An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease	Completed	Boehringer Ingelheim	Phase 3	1969-12-31	To provide access to Viramune and to evaluate the tolerance and safety of Viramune in patients with progressive, symptomatic HIV disease who failed or are intolerant to currently approved treatment for HIV-1 infection and who are unable to participate in another Viramune controlled clinical trial and have a compelling need for anti-HIV treatment.
NCT00002194 ↗	An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.	Completed	Boehringer Ingelheim	Phase 1	1969-12-31	To evaluate the potential pharmacokinetic interaction between nevirapine and clarithromycin, and to determine the effects of nevirapine on cytochrome P450 3A4 (CYP3A4) activity in vivo.
NCT00002368 ↗	The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs	Completed	Boehringer Ingelheim	Phase 3	1969-12-31	To evaluate the tolerance, safety, and effectiveness of Viramune in preventing clinical AIDS progression events or death when used in combination with Lamivudine and background nucleoside therapy.
NCT00002381 ↗	The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine	Completed	Boehringer Ingelheim	Phase 1	1969-12-31	To determine the potential effects of 28 days of nevirapine treatment on the steady-state pharmacokinetics of nelfinavir and of stavudine (d4T), and to further evaluate the pharmacokinetics of nevirapine in combination with nelfinavir, and d4T compared to the historical controls treated with nevirapine but without nelfinavir or d4T. To determine the efficacy of long-term combination therapy of nevirapine, nelfinavir and d4T on viral load in patients who are non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor naive, and have <= 6 months prior d4T exposure at the time of screening.

Clinical Trial Conditions for VIRAMUNE

Condition Name

Condition Name for VIRAMUNE
Intervention	Trials
HIV Infections	30
HIV	3
Healthy	2
Hepatic Insufficiency	2

Condition MeSH

Condition MeSH for VIRAMUNE
Intervention	Trials
HIV Infections	33
Acquired Immunodeficiency Syndrome	8
Infections	3
Infection	3

Clinical Trial Locations for VIRAMUNE

Trials by Country

Trials by Country for VIRAMUNE
Location	Trials
United States	56
Brazil	7
Spain	6
Thailand	5
South Africa	5

Trials by US State

Trials by US State for VIRAMUNE
Location	Trials
California	6
Rhode Island	4
New York	4
Massachusetts	3
Colorado	3

Clinical Trial Progress for VIRAMUNE

Clinical Trial Phase

Clinical Trial Phase for VIRAMUNE
Clinical Trial Phase	Trials
Phase 4	13
Phase 3	6
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for VIRAMUNE
Clinical Trial Phase	Trials
Completed	39
Terminated	3

Clinical Trial Sponsors for VIRAMUNE

Sponsor Name

Sponsor Name for VIRAMUNE
Sponsor	Trials
Boehringer Ingelheim	26
National Institute of Allergy and Infectious Diseases (NIAID)	5
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	5

Sponsor Type

Sponsor Type for VIRAMUNE
Sponsor	Trials
Industry	33
Other	30
NIH	13